Related Experiment Videos
Intravitreal bevacizumab for uveitic choroidal neovascularization
Priyanka P Doctor1, Pooja Bhat, Reema Sayed
1Massachusetts Eye Research and Surgery Institute, Cambridge, Massachusetts 02142, USA.
Purpose:
To report 5 cases of inflammatory choroidal neovascularization (CNV) that were treated with intravitreal bevacizumab.
Methods:
Six eyes of 5 patients with uveitic CNV were treated with 2.5 mg/0.1 mL of intravitreal bevacizumab. Main outcome measures were the changes in BCVA and reduction in the size of the CNV.
Results:
The mean follow-up time was 15.3 months. The mean intravitreal injections administered were 2.7. All patients showed a reduction in the size of the CNV with improvement in BCVA in 60% of cases at the last follow-up.
Conclusion:
Intravitreal bevacizumab may provide an additional strategy in the management of inflammatory CNV.
Related Concept Videos
Open Angle Glaucoma: Treatment
Drugs such as carbonic anhydrase inhibitors, α2- and...
Angle Closure Glaucoma: Treatment
Diabetic Retinopathy
Glaucoma: Overview